| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.36) per share which missed the analyst consensus estim...
On Wednesday, major U.S. indices closed mixed, with the Nasdaq rising 1.1% to 23,043.38 and the S&P 500 slipping nearly 0.6...
Recursion Pharmaceuticals' stock rises on heavy trading volume, with investors eyeing its AI-designed cancer drug REC-3565 ...